Evidence map›Paper›PMID 41387785›Full record

ArticleBMC medical imaging2025

Prediction of EGFR mutation status in non-small cell lung cancer based on multiparametric MRI radiomics.

Yubo Wang, Hao Hu, Yadan Yin, Jiyun Zhang, Yang Fu, Jiageng Li, Xueqing Sun, Mengxue Kong, Bosen Xie, Hai Xu and 1 more

Abstract read
In one paragraph

Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yubo Wang *Kunming Medical University Affiliated Calmette Hospital, Kunming, 650051, China.
Hao Hu *Kunming Medical University Affiliated Calmette Hospital, Kunming, 650051, China.
Yadan Yin *Kunming Medical University Affiliated Calmette Hospital, Kunming, 650051, China.
Jiyun Zhang *Kunming Medical University Affiliated Calmette Hospital, Kunming, 650051, China.
Yang Fu *Kunming Medical University Affiliated Calmette Hospital, Kunming, 650051, China.
Jiageng Li *Kunming Medical University Affiliated Calmette Hospital, Kunming, 650051, China.
Xueqing SunThe First Hospital of Mile, Honghe, 652300, China.
Mengxue KongKunming Medical University Affiliated Calmette Hospital, Kunming, 650051, China.
Bosen XieKunming Medical University Affiliated Calmette Hospital, Kunming, 650051, China.
Hai XuFirst Affiliated Hospital of Nanjing Medical University, Jiangsu, 210029, China. xuhai507@126.com.
Bin YangKunming Medical University Affiliated Calmette Hospital, Kunming, 650051, China. yangbinapple@163.com.

Funding

2024 Senior Health Technology and Medical Discipline Leader of Yunnan Provincial Health Commission D-2024056National Natural Science Foundation of China Project 82160348Yunnan Province Major Special Plan 202302AA310018-D-8Yunnan Province's Xingdian Talent Support Program Youth Talent Project XDYC-QNRC-2022-0608
6 · The paper itself

Abstract

backgroundThe purpose of the study was to establish and validate a model for predicting the mutation status of epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) using magnetic resonance imaging (MRI) radiomics features combined with clinicopathological factors.

methodsOverall, 91 patients with NSCLC (72 in the training cohort and 19 in the validation cohort) were included in this study; 1708 radiomics features were extracted from the MRI (T2W and CET1w) sequences. The variance threshold method combined with the univariate selection method and the least absolute shrinkage and selection operator (LASSO) regression was used to screen important radiomics features, calculate radiomics scores, and construct a radiomics model. Multivariate logistic regression analysis was used to combine radiomics scores (Rad-scores) and independent predictive factors to construct a radiomics nomogram for predicting EGFR mutation status. The predictive performance and clinical practicality of the model were evaluated using the area under the curve (AUC), calibration curves, and clinical decision curves.

resultEGFR mutations were identified in 30.8% (28/91) of patients; 854 radiomics features were extracted from T2WI and CET1w, making a total of 1708 features. First, the variance threshold method was used to screen out features with variance < 0.8, yielding 1702 features. Features with an insignificant differences (p ≥ 0.05) were screened out using the univariate selection method, yielding 43 features. Finally, all features were fitted based on the type of gene mutation using the LASSO algorithm. Thirteen important radiomics features were screened. The radiomics model based on T2WI combined with CET1w provided better classification of EGFR mutant and wild-type, with AUCs of 0.846 and 0.808 in the training and validation cohorts, respectively. The radiomics nomogram model based on T2WI–CET1w radiomics label combination and independent predictors (gender and maximum diameter) for multivariate logistic regression analysis showed higher diagnostic efficiency, with AUCs of 0.880 and 0.859, respectively. The calibration curve showed good predictive performance, and the decision curve indicated that the radiomics nomogram had high clinical benefits.

conclusionThe model based on MRI radiomics shows strong diagnostic efficacy for predicting EGFR mutation status in NSCLC, guiding individualized targeted therapies.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsMultiparametric Magnetic Resonance ImagingAgedErbB ReceptorsFemaleHumansMaleMiddle AgedMutationNomogramsRadiomicsEGFR protein, humanErbB ReceptorsEpidermal growth factor receptorMachine learningMagnetic resonance imagingNon-small cell lung cancerRadiomics

Identifiers

PMID41387785
PMCPMC12699920

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.